Chemo Avoidance Pays Off for Some Women With HER2+ Early BC

In the PHERGAIN trial, nearly all patients who were diverted from chemotherapy prior to surgery for HER2-positive early breast cancer survived without cancer recurrence for 3 years.

Related Keywords

United States , Chicago , Illinois , Madrid , Spain , American , Javier Cort , Kevin Kalinsky , American Society Of Clinical Oncology , Emory University Hospital , Cajal University Hospital , American Society , Clinical Oncology , Lancet Oncology , Breast Cancer , Alignant Breast Neoplasm , Chemotherapy , Biologic Therapy , Cancer , Alignant Neoplasia , Arcinoma , Antineoplastic Drug , Nti Cancer Agents , Evacizumab , Rlotinib , Efitinib , Matinib , Ituximab , U11248 , Unitinib , Rastuzumab , Targeted Therapy , Genomics , Genomic Medicine , Edicine Genomic , Breast , Surgery , Hospitals , Humanized Monoclonal Antibody , Scan , Hormone The ,